SCHEMBL167625

SCHEMBL167625

O=C1c2c[c]ccc2C(=O)c2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
CDC25B P30305 3/20 0.57
MAOA P21397 4/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
MAPT P10636 3/20 0.48
APAF1 O14727 2/20 0.48
TDP2 O95551 2/20 0.48
NPC1 O15118 2/20 0.48
MAPK1 P28482 2/20 0.48
KDM4E B2RXH2 2/20 0.48
LMNA P02545 2/20 0.48
POLB P06746 2/20 0.48
S100A4 P26447 2/20 0.48
BLM P54132 2/20 0.48
CES2 O00748 1/20 0.48
TERT O14746 1/20 0.48
PLIN1 O60240 1/20 0.48
S1PR4 O95977 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL693395 0.98 MEN1 (0.55) MEN1KMT2ACDC25BMAOARAB9A
SCHEMBL1929100 0.93 MEN1 (0.55) MEN1KMT2ACDC25BMAOARAB9A
SCHEMBL7148476 0.93 MEN1 (0.43) MEN1KMT2ACDC25BMAOARAB9A
SCHEMBL9799712 0.87 MEN1 (0.36) MEN1KMT2ACDC25BMAOARAB9A
SCHEMBL8659735 0.80 ADORA2A (0.41) MEN1KMT2ACDC25BMAOARAB9A
SCHEMBL20774014 0.79 MEN1 (0.36) MEN1KMT2ACDC25BMAOARAB9A
SCHEMBL1350657 0.79 MEN1 (0.36) MEN1KMT2ACDC25BMAOARAB9A
Anthraquinone SCHEMBL9208192 0.79 MEN1 (0.92) MEN1KMT2ACDC25BMAOARAB9A
Anthraquinone SCHEMBL6415478 0.79 MEN1 (0.92) MEN1KMT2ACDC25BMAOARAB9A
Anthraquinone SCHEMBL30692662 0.79 MEN1 (0.92) MEN1KMT2ACDC25BMAOARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11897977-B2 Photolabile barbiturate compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2024-02-13 US claimed
US-11370940-B2 Adhesive article and methods of making and using the same 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-06-28 US claimed
EP-3746489-B1 PHOTOLABILE BARBITURATE COMPOUNDS 3M INNOVATIVE PROPERTIES CO (US) 2022-03-30 EP claimed
US-20210277283-A1 ADHESIVE ARTICLE AND METHODS OF MAKING AND USING THE SAME 3M INNOVATIVE PROPERTIES COMPANY 2021-09-09 US claimed
CN-108348403-B Redox polymerizable compositions containing photolabile transition metal complexes 3M创新有限公司 2021-06-18 CN claimed
CN-108348404-B Redox polymerizable dental compositions utilizing photolabile transition metal complexes 3M创新有限公司 2021-06-08 CN claimed
CN-110709486-B Adhesive articles and methods of making and using the same 3M创新有限公司 2021-04-16 CN claimed
US-20210040240-A1 PHOTOLABILE BARBITURATE COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY 2021-02-11 US claimed
EP-3746489-A1 PHOTOLABILE BARBITURATE COMPOUNDS 3M Innovative Properties Company (US) 2020-12-09 EP claimed
EP-3746490-A1 PHOTOLABILE BETA-DICARBONYL COMPOUNDS 3M Innovative Properties Company (US) 2020-12-09 EP claimed
EP-0479892-A1 FUSED-RING ARYL SUBSTITUTED IMIDAZOLES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1992-04-15 EP claimed
EP-0275077-B1 ANTHRAQUINONE COMPOUNDS AND POLARIZING FILM CONTAINING THE SAME MITSUBISHI KASEI CORPORATION (JP) 1992-02-05 EP claimed
WO-1991015206-A1 TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-17 WO claimed
WO-1991014367-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-03 WO claimed
WO-1991000281-A2 FUSED-RING ARYL SUBSTITUTED IMIDAZOLES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-01-10 WO claimed
US-4921959-A POLARIZING FILMS, DICHROMISM MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1990-05-01 US claimed
EP-0275077-A1 Anthraquinone compounds and polarizing film containing the same MITSUBISHI KASEI CORPORATION (JP) 1988-07-20 EP claimed
EP-0019285-B1 PROCESS FOR PREPARING ASYMMETRICAL VAT DYESTUFFS OF THE ANTHRAQUINONE SERIES AND THEIR USE IN DYEING AND PRINTING CIBA-GEIGY AG (CH) 1984-05-09 EP claimed
US-4329456-A ACYLATION WITHOUT INTERMEDIATE ISOLATION CIBA-GEIGY AG (CH) 1982-05-11 US claimed
US-4052371-A AZO PIGMENT OR DYE HAVING A NAPHTHYL-QUINAZALONE COUPLING COMPONENT BASF AKTIENGESELLSCHAFT (DT) 1977-10-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11897977-B2 Photolabile barbiturate compounds PPOX, CBR1, CBR3 MEN1 4096/4885KMT2A 3332/4885CDC25B 1466/4885
US-20210040240-A1 PHOTOLABILE BARBITURATE COMPOUNDS PPOX, CBR1, CBR3 MEN1 4096/4885KMT2A 3332/4885CDC25B 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.